TABLE 4.

Ranking C1C2-specific MAbs by ADCC breadth and potency^a

Rank	Antibody	Study	Score	No. of strains recognized
1	A32		6.62	7
2	CH38	RV144	6.28	6
3	DH677.3	RV305	4.56	7
4	DH697	RV305	2.70	7
5	DH677.2	RV305	1.72	5
6	DH838	RV305	1.62	4
7	DH677.4	RV305	1.30	6
8	DH695	RV305	0.86	7
9	DH688.1	RV305	0.66	6
10	DH694	RV305	0.58	5
11	DH705.5	RV305	0.52	5
12	DH705.4	RV305	0.46	6
13	DH690	RV305	0.36	7
14	DH692	RV305	0.08	6
15	DH693	RV305	0.06	7
16	DH886	RV305	−0.08	5
17	DH688.2	RV305	−0.30	5
18	DH836	RV305	−0.32	5
19	CH57	RV144	−0.48	5
20	CH90	RV144	−1.06	5
21	CH54	RV144	−1.20	5
22	DH689.2	RV305	−1.42	6
23	DH689.1	RV305	−1.68	6
24	DH677.1	RV144	−2.20	2
25	DH687.2	RV305	−2.70	2

^aRV305 and RV144 C1C2-specific MAbs were assayed for antibody-dependent cellular cytotoxicity against AE.CM235, B.WITO, C.TV-1, C.MW965, C.1086C, C.DU151, and C.DU422 infectious molecular clone-infected CEM.NKR_CCR5 cells. MAbs were ranked using an ADCC score that accounts for breadth and potency (see Materials and Methods). Number of strains recognized was determined by ADCC endpoint concentration.